| Spotlight on Science is a quarterly science and research digest from the FDA Center for Tobacco Products. In This Issue... According to results from the latest National Youth Tobacco Survey (NYTS), 1.73 million fewer middle and high school students are using tobacco products in 2020 compared to 2019. Learn more in this latest issue of Spotlight on Science, a quarterly research and science digest from FDA's Center for Tobacco Products (CTP). Youth Overall Tobacco Use and ENDS Use Both Declined in 2020 FDA and the Centers for Disease Control and Prevention (CDC) released findings on youth overall tobacco use from the 2020 National Youth Tobacco Survey (NYTS), which show 1.73 million fewer middle and high school students are using tobacco products in 2020 compared to 2019. A decrease in youth use of e-cigarettes (1.80 million) accounted for a large portion of the decline in overall youth tobacco use, although the number of current e-cigarette users remains disconcertingly high (3.58 million). Additionally, from 2019 to 2020, teen use of combustible tobacco products, multiple tobacco products, cigars, and smokeless tobacco decreased significantly. Despite the declines in youth use of combustible tobacco products, there was no change in teen cigarette smoking from 2019 to 2020. Nor was there a change in youth use of hookah, pipe tobacco, or heated tobacco products from 2019 to 2020. Furthermore, rates of combustible tobacco use remain concerningly high: among youth who use any tobacco product in 2020, about 42 percent smoke combustible products. The data also show an alarming surge in the number of youth who use disposable e-cigarettes and flavored products. FDA and CDC published detailed information on the 2020 NYTS in a December 2020 article on youth overall tobacco use and a September 2020 article on youth e-cigarette use. FDA has published a web feature on youth tobacco use and an infographic on youth e-cigarette use to promote these findings further. FDA Issues Marketing Order for IQOS 3 System Holder and Charger On Dec. 7, FDA issued a marketing order to Philip Morris Products S.A. authorizing the sale of the IQOS 3 System Holder and Charger. Compared to the previous version authorized in April 2019, the newly authorized version has minor design differences, including how the holder inserts into the charger, changes to the charging connectors and LED indicator lights, a new touch feedback feature, and an option to reduce the perceived heat from the tobacco aerosol inhaled by users. Data on product use in international markets suggest no differences among user populations from the previous version of the device holder and charger, including no new concerns regarding product initiation or use among youth and young adults. Following FDA's scientific review of the application, the agency found, among other things, that the modifications to the device do not raise new concerns related to safety, health effects, product quality, or product misuse. Importantly, this action does not mean this product is safe or "FDA-approved." There are no safe tobacco products, and those who do not use tobacco products should not start. More About CTP Research Recent Publications by CTP Researchers For recent research publications, please follow this link. Research Opportunities to Explore In support of its mission to develop regulation rooted in science, CTP seeks new research to address key areas of tobacco regulatory science such as toxicity, addiction, health effects, behavior, communications, marketing influences, and impact analysis of regulatory actions. CTP encourages research studies to include, where appropriate to the research question, populations of special relevance, including (but not limited to): youth, socioeconomically disadvantaged populations, racial/ethnic minorities, underserved rural populations, people with co-morbid mental health conditions and/or substance use disorders, military/veteran populations, pregnant women or women of reproductive age, and sexual and gender minorities. Featured below are some current CTP funding opportunities. You can find more information by clicking on the appropriate funding opportunity announcement (FOA) number. More information on CTP-funded research can be found on the center's website. NIH Tobacco Regulatory Science Program The Tobacco Regulatory Science Program, FDA's partnership with NIH to foster tobacco regulatory research, offers funding for scientists whose research can inform CTP's regulatory activities. Tobacco Regulatory Science (R01 Clinical Trial Optional) Application due date: February 13, 2021, by 5:00 PM local time of applicant organization. Notice of Special Interest: Research to Advance the Understanding of Tobacco Product Pharmacokinetic Research (NOT-OD-20-081) Application due date: February 13, 2021, by 5:00 PM local time of applicant organization. Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 Clinical Trial Not Allowed) (RFA-OD-19-021) Application due dates: March 8, 2021, by 5:00 PM local time of applicant organization. Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) (RFA-OD-19-022) Application due dates: March 8, 2021, by 5:00 PM local time of applicant organization. FDA Support for Conferences and Scientific Meetings (R13) Application due dates: April 12, 2021; October 12, 2021; April 12, 2022; and October 11, 2022 by 11:59 p.m. EST. Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01; RFA-OD-20-008 or RFA-OD-20-011) Application due dates: Feb. 8, 2021, Oct. 8, 2021, and July 8, 2022 by 5:00 p.m. local time of applicant organization. Pathway to Independence Award in Tobacco Regulatory Research (K99/R00; RFA-OD-20-009 or RFA-OD-20-010) Application due dates: Feb. 8, 2021, Oct. 8, 2021, and July 8, 2022 by 5:00 p.m. local time of applicant organization. Spotlight on Science is a quarterly science and research digest from FDA's Center for Tobacco Products. Note: The contents of publications discussed in this newsletter are the responsibility of their authors alone, and findings and conclusions are those of the authors and do not necessarily represent the views of FDA. | 
No comments:
Post a Comment